Data coverage, completeness and provenance for RADIOPHARM THERANOSTICS LIMITED in the Stock Market API — Health Care · Biotechnology.
Source date: 2026-10-30T05:10:11. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-30 | 0.0050 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-29 | 0.0040 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-28 | 0.0045 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-27 | 0.0040 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-26 | 0.0050 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/RAD/prices · Price parameters and adjustment semantics
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Employees: 14 · Website: https://www.radiopharmtheranostics.com · Profile fields populated: 75%
Share of stored fields populated in the anchor reporting period (FY2026), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/RAD/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2026 (AUD) | 2026-06-30 | 27 | yfinance | ||||
| FY2025 (AUD) | 2025-06-30 | 27 | yfinance | ||||
| FY2024 (AUD) | 2024-06-30 | 27 | yfinance | ||||
| FY2023 (AUD) | 2023-06-30 | 28 | yfinance | ||||
| FY2022 (AUD) | 2022-06-30 | 28 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/RAD
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/RAD/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/RAD/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/RAD/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/RAD/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/RAD
Free tier — instant API key. Built for AI agents.